PortfoliosLab logo
NRBO vs. RLAY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between NRBO and RLAY is 0.14, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

NRBO vs. RLAY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in NeuroBo Pharmaceuticals, Inc. (NRBO) and Relay Therapeutics, Inc. (RLAY). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Fundamentals

Market Cap

NRBO:

$20.33M

RLAY:

$514.33M

EPS

NRBO:

-$4.29

RLAY:

-$2.20

PS Ratio

NRBO:

0.00

RLAY:

66.98

PB Ratio

NRBO:

1.32

RLAY:

0.73

Total Revenue (TTM)

NRBO:

$0.00

RLAY:

$7.68M

Gross Profit (TTM)

NRBO:

-$6.00K

RLAY:

-$933.00K

EBITDA (TTM)

NRBO:

-$16.33M

RLAY:

-$372.12M

Returns By Period


NRBO

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

3Y*

N/A

5Y*

N/A

10Y*

N/A

RLAY

YTD

-27.18%

1M

-8.81%

6M

-36.17%

1Y

-53.20%

3Y*

-43.09%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


NeuroBo Pharmaceuticals, Inc.

Relay Therapeutics, Inc.

Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

NRBO vs. RLAY — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NRBO
The Risk-Adjusted Performance Rank of NRBO is 3030
Overall Rank
The Sharpe Ratio Rank of NRBO is 2828
Sharpe Ratio Rank
The Sortino Ratio Rank of NRBO is 3333
Sortino Ratio Rank
The Omega Ratio Rank of NRBO is 3333
Omega Ratio Rank
The Calmar Ratio Rank of NRBO is 2424
Calmar Ratio Rank
The Martin Ratio Rank of NRBO is 3030
Martin Ratio Rank

RLAY
The Risk-Adjusted Performance Rank of RLAY is 1717
Overall Rank
The Sharpe Ratio Rank of RLAY is 1818
Sharpe Ratio Rank
The Sortino Ratio Rank of RLAY is 1616
Sortino Ratio Rank
The Omega Ratio Rank of RLAY is 1919
Omega Ratio Rank
The Calmar Ratio Rank of RLAY is 1414
Calmar Ratio Rank
The Martin Ratio Rank of RLAY is 1818
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

NRBO vs. RLAY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for NeuroBo Pharmaceuticals, Inc. (NRBO) and Relay Therapeutics, Inc. (RLAY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.



Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

NRBO vs. RLAY - Dividend Comparison

Neither NRBO nor RLAY has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

NRBO vs. RLAY - Drawdown Comparison


Loading data...

Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

NRBO vs. RLAY - Volatility Comparison


Loading data...

Financials

NRBO vs. RLAY - Financials Comparison

This section allows you to compare key financial metrics between NeuroBo Pharmaceuticals, Inc. and Relay Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M202120222023202420250
7.68M
(NRBO) Total Revenue
(RLAY) Total Revenue
Values in USD except per share items